Further Information
Toll-like receptor 1, Toll/interleukin-1 receptor-like protein, TIL, CD281, Tlr1
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:50~100
Higher animals establish host defense by orchestrating innate and adaptive immunity. This is mediated by professional antigen presenting cells, i.e. dendritic cells (DCs). DCs can incorporate pathogens, produce a variety of cytokines, maturate, and present pathogen-derived peptides to T cells, thereby inducing T cell activation and differentiation. These responses are triggered by microbial recognition through type I transmembrane proteins, Toll-like receptors (TLRs) on DCs. TLRs consist of ten members and each TLR is involved in recognizing a variety of microorganism-derived molecular structures. TLR ligands include cell wall components, proteins, nucleic acids, and synthetic chemical compounds, all of which can activate DCs as immune adjuvants. Each TLR can activate DCs in a similar, but distinct manner. For example, TLRs can be divided into subgroups according to their type I interferon (IFN) inducing ability. TLR2 cannot induce IFN-alpha or IFN-beta, but TLR4 can lead to IFN-beta production. Meanwhile, TLR3, TLR7, and TLR9 can induce both IFN-alpha and IFN-beta. Recent evidences suggest that cytoplamic adapters for TLRs are especially crucial for this functional heterogeneity.
- Hajjar, A.M., et al., J. Immunol. 166(1):15-19 (2001).
- Ozinsky, A., et al., Proc. Natl. Acad. Sci. U.S.A. 97(25):13766-13771 (2000).
Supplied in PBS with 0.09% (W/V) sodium azide.
batch dependent
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
This Mouse TLR1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 764-795 amino acids from the C-terminal region of mouse TLR1.
21897
Toll-like receptor 1
Tlr1
Mus musculus
Liquid
PREDICTED MOLECULAR WEIGHT:
91 kDa
Q9EPQ1
This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunology,Signal Transduction
Q9EPQ1
Optimal dilutions for each application to be determined by the researcher.